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Identity 
Other names: PIM 




PIM1 is a single gene with 5 introns and 6 exons that
span 5 kb of DNA in the human genome (Meeker et al., 
1987).  
The gene starts at 37137922 and ends at 37143204 base 
pairs from pter. It is highly conserved evolutionarily 
across species. 
Transcription 




Size: 313 amino acids; molecular weight: 36 kDa. 
The PIM1 gene has six exons, but there are two 
isoforms of PIM1 protein, 34 kDa and 44 kDa, due to 
protein synthesis using alternative sites of transltion 
initiation (Saris et al., 1991).  
Both proteins show comparable kinase activities in 
vitro, but the 44 kDa isoform contains an N-terminal 
proline-rich motif that binds the ETK SH3 domain, ad 
is recruited to the plasma membrane (Xie et al., 2006). 
Expression 
The kinase activity of all the PIM proteins is 
constitutively active, and there are no regulatory 
domains in the amino acid sequences of the PIM 
proteins.  
Thus, unlike other kinases that are regulated by 
phosphorylation or binding to the plasma membrane, 
the activity of PIM1 is regulated primarily by 
transcription, translation and proteosomal degradation 
(Amaravadi and Thompson, 2005).  
The gene expression of PIM1 is increased by various 
cytokines, mitogens and hormones such as G-CSF, 
GM-CSF, erythropoietin, interleukins, Con A, PMA, 
interferons, and prolactin (Wang et al., 2001; Hogan et 
al., 2008; White, 2003).  
These factors act through the JAK/STAT pathway. The
upregulation of PIM1 gene expression results from the 
binding site of STAT3 or STAT5 to the PIM1 gene 
promoter, and the ISFR/GAS-sequence (IFN-γ 
activation sequence) is an important binding site (Block 
et al., 2012; Matikainen et al., 1999; Yip-Schneider et 
al., 1995).  
PIM1 phosphorylates and stabilizes SOCS proteins 
(suppressor of cytokine signaling) to provide negative 
feedback regulation of the JAK/STAT pathway (Peltola 
et al., 2004). 
NF-κB, as a downstream transcription factors, could 
also activate PIM1. In solid tumors, hypoxia would 
induce the PIM1 expression, independently of HIF1α 
and by Krueppel-like factor 5 (KLF5) upon DNA 
damage (Chen et al., 2009a). ERG, as a transcription 
factors, also plays a role in PIM1 expression in the
initial stages of prostate carcinogenesis (Magistroni et 
al., 2011). 
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Because of multiple copies of AUUU(A) motifs in the 
3'UTR and GC-rich regions in the 5'UTR, mRNA of 
PIM genes are short lived (Wang et al., 2005).  
Translation of PIM1 seems to be cap-dependent, and 
overexpression of elF4E would increase PIM1 protein 
level (Hoover et al., 1997).  
PIM RNA transcripts are regulatory targets of different 
miRNAs such as microRNAs miR1, miR-210, miR-
33a, and miR328, implicating another layer of PIM 
expression regulation (Eiring et al., 2010; Huang et al., 
2009; Nasser et al., 2008; Thomas et al., 2012). 
At the post-translational level, the short half-life of 
PIM1 is primarily regulated by proteasomal 
degradation. PIM1 protein can be stabilized by the 
binding to HSP90 (Mizuno et al., 2001).  
On the other hand, binding to HSP70 would induce the 
ubiquitylation of PIM1 and proteasomal degradation 
(Shay et al., 2005).  
Also, in hypoxia, ubiquitin-mediated proteasomal 
degradation of PIM is prevented by HSP90 (Mizuno et 
al., 2001). PIM1 protein stability is further regulated by 
its phosphorylation status. PIM1 is able to 
autophosphorylate (Bullock et al., 2005). 
Phosphorylation by itself and/or other unknown kinases 
is important for PIM1 protein stability and function 
because PP2A phosphatase negatively regulates PIM1 
stability (Losman et al., 2003). 
Localisation 
PIM1 is highly expressed in lymphoid and 
hematopoietic tissues (bone marrow, thymus, spleen, 
and fetal liver) (Eichmann et al., 2000) as well as in 
some non-hematopoietic tissues (e.g., hippocampus, 
oral epithelium, and the prostate gland). In some 
myeloid and lymphoid leukemia cell lines, prostate 
cancer cell lines, and also HeLa cells, PIM have also 
been detected. The PIM1 protein can be detected 
subcellularly in the cytoplasm and the nucleus. 
Function 
PIM1 phosphorylates a large subset of cellular 
substrates and thus regulates many different cellular 
processes such as cell cycle progression, cellular 
division, differentiation and apoptosis. 
One of the cell-cycle-related targets of PIM1 is p21waf1 
(Wang et al., 2002; Zhang et al., 2007). By 
phosphorylating the CDK inhibitor p21waf1 on T145, 
PIM1 lead to the nuclear export and inactivation of 
p21waf1. Phosphorylation of another CDK inhibitor 
p27Kip1 at Thr157 and Thr198 would induce its 
proteasomal degradation and cell cycle progression.  
Moreover, PIM1 seems to phosphorylate and inactivate 
the transcription factors of p27Kip1,  
FoxO1a and FoxO3a (Morishita et al., 2008). Another 
mechanism of p27Kip1 regulation is the phosphorylation 
of SKP2 at Thr417, which control its stability and 
ability to degrade p27 (Cen et al., 2010). Additionally,  
the phosphorylation of Cdc25A and Cdc25C would 
induce G1/S and G2/M transition, respectively 
(Bachmann et al., 2004).  
PIM1 also implicate in mitosis promotion by interacts 
with dynein/dynactin and HP1β (Magnuson et al., 
2010). 
Moreover, PIM1 is involved in genomic instability. By 
interaction with NuMA (nuclear mitotic apparatus 
protein), overexpression of PIM1 causes the loss of 
checkpoint control (Bhattacharya et al., 2002).  
Consequently, cells with abnormal mitotic spindles are
not arrested in mitosis, producing polyploid and 
multinucleated daughter cells. 
PIM1 can also act as an oncogenic survival factor 
because of its function in blocking apoptotic cell death. 
It is consensus that phosphorylation of BAD at S112 
would induce its proteasomal degradation and thus 
shifts the apoptosis threshold (Peltola et al., 2004).  
The proapoptotic activity of ASK1 and PRAS40 would 
also be impaired by PIM1 phosphorylation (Gu et al., 
2009; Zhang et al., 2009).  
Through inactivation of ASK1 and subsequently less 
phosphorylation of the stress kinases JNK and p38, 
caspase-3 activation would be less and thus reduce cell 
death.  
Moreover, the block of MDM2 and p53 degradation by 
PIM1 may induce senescence in embryonic fibroblasts 
and cancer cells (Hogan et al., 2008). 
When bound to MYC at the E-box, PIM1 would 
participate in the complex's phosphorylation of histone 
H3 at S10 and thus participate in the stimulation of 
transcription of a specific subset of MYC-dependent 
genes (Zippo et al., 2007). 
Additionally, PIM1 influences the activity of a number 
of transcriptional regulators, such as HP-1, PAP-1, 
TFAF2/SNX6, NFATc1, p100, RUNX, SOCS1, 
RelA/p65 and c-Myb (Bhattacharya et al., 2002; Evans 
and Fox, 2007; Ishibashi et al., 2001; Kim et al., 2010; 
Rainio et al., 2002; Winn et al., 2003). 
PIM kinases also phosphorylate 4E-BP1, inhibiting its 
binding to elF-4E.  
Since elF-4E is a rate-limiting factor in protein 
synthesis, PIM kinases may also regulate 5' cap-
dependent translation (Beharry et al., 2011). 
Implicated in 
t(3;6)(q27;p21.2) in diffuse large B-cell 
lymphoma (DLCL); chimeric BCL6 / 
PIM1 
Note 
Only 1 case to date. 
Hybrid/Mutated gene 
5' PIM1 fused to 3' BCL6; the substitution of the 
promoter of BCL6 causes deregulation of BCL6. 
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Myeloid and lymphoid leukemias and 
other lymphomas 
Oncogenesis 
PIM1 induces anti-apoptotic oncogenes such as 
BCR/ABL, FLT2, CBL or JAK2 (Adam et al., 2006; 
Mizuki et al., 2003; Naramura et al., 2011; 
Nieborowska-Skorska et al., 2002; Wernig et al., 2008). 
PIM1 mRNA is upregulated in acute myeloid leukemia 
(AML) along with MLL gene rearrangements, e.g., 
MLL/AF9 or MLL/ENL (Chen et al., 2008). The 
reason for PIM1 levels increase seems to be the 
constitutive activation of FLT3 or Hoxa9 (Hu et al., 
2007). Additionally, PIM1 also involve in the several 
B-cell developmental disorders that are related to 
Kaposi sarcoma associated herpesvirus (KSHV) or the 




In more half of the prostate cancer samples, PIM1 is 
showed a relatively overexpression compared to benign 
lesions and the expression elevation correlated with a 
poor therapeutic outcome (Dhanasekaran et al., 2001). 
Oncogenesis 
In mouse model, the synergistic effects of PIM1 and 
MYC showed obvious co-regulation in prostate cancer. 
The molecular mechanism for the oncogenic activity 
might because PIM1 phosphorylation of c-MYC would 
increase its half-life and also because PIM1 
enhancement of transcriptional activity of c-MYC 
(Chen et al., 2009b; Mumenthaler et al., 2009). 
Moreover, PIM1 kinase is related to chemoresistance i  
prostate cancer cells, which is related to relatively 
aggressive or hormone-refractory prostate cancers. The 
high level of expression of PIM1 in high grade prostate 
intraepithelial neoplasia may indicate a role of PIM1 in 
the early prostate carcinogenesis. PIM1 is also found to 
be upregulated in patients undergoing androgen 
ablation therapy (van der Poel et al., 2010). 
Pancreatic cancer 
Note 
Hypoxia-promoted genetic instability 
Oncogenesis 
PIM1 increases in hypoxic condition, independently of 
HIF-1α (Reiser-Erkan et al., 2008). It is now proposed 
as a prognostic marker. Increase in PIM1 expression 
may partly account for resistance to chemotherapy. 
Sporadic malignant tumors 
Oncogenesis 
Overexpression of PIM1 is founded in gastric 
carcinoma, squamous cell carcinoma, colorectal 
carcinoma, liver carcinoma (Shah et al., 2008), 
liposarcoma (Nga et al., 2010), and bladder cancer 
(Guo et al., 2010). 
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